[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-retatrutide-triumph-1-results-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":274,"_id":275,"_source":276,"_file":277,"_stem":278,"_extension":279},"\u002Fblog\u002Fzh\u002Fretatrutide-triumph-1-results","zh",false,"","Retatrutide TRIUMPH-1:三期数据,和那个不能忽略的星号","本文属于一般性科普,不是医疗建议,也不是鼓励你去获取或使用任何东西。Retatrutide 仍处于试验阶段,尚未获批。下面这些数字,是一家公司从自己的试验里报告出来的结果,既不是对任何疗效的承诺,也不是用药指导。","研究","tabler:chart-line","#4C9F70","2026-07-01","2026年7月","7 min","myPeptides Team","\u002Fassets\u002Freta_triumph_hero.png",{"type":19,"children":20,"toc":265},"root",[21,28,33,39,44,124,129,138,143,148,153,158,163,168,182,187,192,197,218,223],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31],{"type":27,"value":32},"一句话版本:2026 年 5 月 21 日,礼来公布了 TRIUMPH-1 的顶线结果——这是 Retatrutide 针对肥胖的首个三期试验。最抢眼的一条是:在最高的 12 mg 剂量下、历时 80 周,平均减重达到 28.3%,并且有 45.3% 的受试者减掉了至少 30% 的体重——这个幅度过去只属于减重手术。数字是真的,也确实很大。而那个星号是:Retatrutide 至今仍未获批,这只是公司的一份新闻稿,而不是经过完整同行评审的数据集;今天任何打着这个名号卖的东西,都是未获批的灰色市场货。",{"type":22,"tag":34,"props":35,"children":37},"h2",{"id":36},"礼来报告的那些数字",[38],{"type":27,"value":36},{"type":22,"tag":23,"props":40,"children":41},{},[42],{"type":27,"value":43},"TRIUMPH-1 招募了 2,339 名成年人,他们要么肥胖,要么超重并伴有与体重相关的疾病;试验在 80 周里测试了这款每周一次注射剂的三种剂量。",{"type":22,"tag":45,"props":46,"children":47},"table",{},[48,67],{"type":22,"tag":49,"props":50,"children":51},"thead",{},[52],{"type":22,"tag":53,"props":54,"children":55},"tr",{},[56,62],{"type":22,"tag":57,"props":58,"children":59},"th",{},[60],{"type":27,"value":61},"指标(顶线)",{"type":22,"tag":57,"props":63,"children":64},{},[65],{"type":27,"value":66},"结果",{"type":22,"tag":68,"props":69,"children":70},"tbody",{},[71,85,98,111],{"type":22,"tag":53,"props":72,"children":73},{},[74,80],{"type":22,"tag":75,"props":76,"children":77},"td",{},[78],{"type":27,"value":79},"12 mg、80 周平均减重",{"type":22,"tag":75,"props":81,"children":82},{},[83],{"type":27,"value":84},"约 28.3%(约 70 磅)",{"type":22,"tag":53,"props":86,"children":87},{},[88,93],{"type":22,"tag":75,"props":89,"children":90},{},[91],{"type":27,"value":92},"减掉体重 ≥30% 的受试者比例",{"type":22,"tag":75,"props":94,"children":95},{},[96],{"type":27,"value":97},"45.3%",{"type":22,"tag":53,"props":99,"children":100},{},[101,106],{"type":22,"tag":75,"props":102,"children":103},{},[104],{"type":27,"value":105},"高 BMI 组延长至 104 周",{"type":22,"tag":75,"props":107,"children":108},{},[109],{"type":27,"value":110},"最高约 30.3%(约 85 磅)",{"type":22,"tag":53,"props":112,"children":113},{},[114,119],{"type":22,"tag":75,"props":115,"children":116},{},[117],{"type":27,"value":118},"试验规模",{"type":22,"tag":75,"props":120,"children":121},{},[122],{"type":27,"value":123},"2,339 名成年人",{"type":22,"tag":23,"props":125,"children":126},{},[127],{"type":27,"value":128},"Retatrutide 是一款三重激动剂:一个分子同时作用于 GIP、GLP-1 和胰高血糖素三种受体。正是胰高血糖素这第三个靶点,被认为让它比之前的 GLP-1 以及 GLP-1\u002FGIP 药物\"下手更狠\"。就目前这些顶线数据而言,它是迄今公布三期数据的减重药里最有效的一款。",{"type":22,"tag":23,"props":130,"children":131},{},[132],{"type":22,"tag":133,"props":134,"children":137},"img",{"alt":135,"src":136},"减重曲线一路向下,旁边是逐渐纤细的身形剪影","\u002Fassets\u002Freta_triumph_chart.png",[],{"type":22,"tag":34,"props":139,"children":141},{"id":140},"没人写进标题的那个星号",[142],{"type":27,"value":140},{"type":22,"tag":23,"props":144,"children":145},{},[146],{"type":27,"value":147},"有三件事会给这份兴奋降降温,也正是我们选择冷静报道它的原因。",{"type":22,"tag":23,"props":149,"children":150},{},[151],{"type":27,"value":152},"第一,它没获批。三期顶线数据是申报路上的一个里程碑,而不是终点线。礼来还得递交申请,FDA 还得审,现实点看,这些都要往后拖。在那之前,不存在合法的、凭处方开出的减重 Retatrutide。",{"type":22,"tag":23,"props":154,"children":155},{},[156],{"type":27,"value":157},"第二,\"顶线\"不等于完整数据集。新闻稿给你的是包装得最漂亮的那几个头条数字。完整结果、安全性细节,以及那份永远最关键的脱落率与不良事件明细,都得等到后面——在某场医学大会上、在某本期刊里才会揭晓。把这 28.3% 当成\"有希望但仍是初步\"的结论,而不是板上钉钉的定论。",{"type":22,"tag":23,"props":159,"children":160},{},[161],{"type":27,"value":162},"第三,也是最实际的一点:眼下市面上流通的全是灰色市场货。正因为真正的药还没获批,网上打着 \"retatrutide\" 名头卖的,是不受监管的研究级原料,成分和纯度都成谜。试验里那些数字,是用一种成分明确的化合物、在临床环境下按剂量给药并全程监测得出的。它们完全说明不了论坛上某人卖的那支西林瓶到底是什么。",{"type":22,"tag":34,"props":164,"children":166},{"id":165},"数字没覆盖到的那些部分",[167],{"type":27,"value":165},{"type":22,"tag":23,"props":169,"children":170},{},[171,173,180],{"type":27,"value":172},"疗效只是一款药的一半。这一类药物已知的那些取舍,在这里同样适用。副作用主要集中在肠胃:恶心、呕吐、腹泻、便秘,和剂量相关,而且在加量阶段最难受。此外,在这些药上快速掉秤,减掉的不只有脂肪,还有瘦体重;掉的体重里相当一部分可能是肌肉——这也是为什么\"蛋白质\"和\"抗阻训练\"会被反复提起。关于掉肌肉这一点,以及二期和三期数据之间的区别,我们在",{"type":22,"tag":174,"props":175,"children":177},"a",{"href":176},"\u002Fblog\u002Fretatrutide-liver-damage-myths",[178],{"type":27,"value":179},"Retatrutide 肝损伤事实核查",{"type":27,"value":181},"里聊得更透。",{"type":22,"tag":34,"props":183,"children":185},{"id":184},"接下来会发生什么",[186],{"type":27,"value":184},{"type":22,"tag":23,"props":188,"children":189},{},[190],{"type":27,"value":191},"TRIUMPH-1 只是一个更大项目的第一批数据。礼来已经预告,2026 年晚些时候还会有更多:面向 2 型糖尿病人群的 TRIUMPH-2,以及面向已确诊心血管疾病人群的 TRIUMPH-3。这两项很关键,因为糖尿病和心脏结局数据,才能把一个减重数字撑成一个更全面的论据。等 TRIUMPH-1 的完整数据在大会上亮相,独立研究者也就能亲自去抠它的安全性和持久性,而不必对着一份新闻稿照单全收。",{"type":22,"tag":34,"props":193,"children":195},{"id":194},"一句话总结",[196],{"type":27,"value":194},{"type":22,"tag":23,"props":198,"children":199},{},[200,202,208,210,216],{"type":27,"value":201},"28.3% 确实是个大数字,就现有数据看,Retatrutide 像是目前最强的一款肠促胰素类药物。但它同样没获批,目前也只公布了顶线数据,今天更不可能通过受监管的渠道买到。看数据,和看一个购买页面,是两件截然不同的事。想了解已发表文献里报告的剂量,可以看我们的 ",{"type":22,"tag":174,"props":203,"children":205},{"href":204},"\u002Fglp1\u002Fretatrutide",[206],{"type":27,"value":207},"Retatrutide 资料页",{"type":27,"value":209},";想从零开始搞懂这一类药,先从",{"type":22,"tag":174,"props":211,"children":213},{"href":212},"\u002Fwhat-are-peptides",[214],{"type":27,"value":215},"什么是肽",{"type":27,"value":217},"看起。",{"type":22,"tag":34,"props":219,"children":221},{"id":220},"参考来源",[222],{"type":27,"value":220},{"type":22,"tag":224,"props":225,"children":226},"ul",{},[227,241,253],{"type":22,"tag":228,"props":229,"children":230},"li",{},[231,233],{"type":27,"value":232},"礼来(投资者新闻稿),2026 年 5 月 21 日,",{"type":22,"tag":174,"props":234,"children":238},{"href":235,"rel":236},"https:\u002F\u002Finvestor.lilly.com\u002Fnews-releases\u002Fnews-release-details\u002Flillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",[237],"nofollow",[239],{"type":27,"value":240},"Retatrutide delivered powerful weight loss in pivotal phase-3 obesity trial",{"type":22,"tag":228,"props":242,"children":243},{},[244,246],{"type":27,"value":245},"AJMC,",{"type":22,"tag":174,"props":247,"children":250},{"href":248,"rel":249},"https:\u002F\u002Fwww.ajmc.com\u002Fview\u002Fretatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial",[237],[251],{"type":27,"value":252},"Retatrutide achieves up to 30.3% average weight loss in phase-3 TRIUMPH-1",{"type":22,"tag":228,"props":254,"children":255},{},[256,258],{"type":27,"value":257},"BioPharma Dive,",{"type":22,"tag":174,"props":259,"children":262},{"href":260,"rel":261},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Flillys-retatrutide-tripleG-phase3-obesity-data\u002F820851\u002F",[237],[263],{"type":27,"value":264},"Lilly's triple-acting obesity drug hits goal in phase-3 trial",{"title":7,"searchDepth":266,"depth":266,"links":267},2,[268,269,270,271,272,273],{"id":36,"depth":266,"text":36},{"id":140,"depth":266,"text":140},{"id":165,"depth":266,"text":165},{"id":184,"depth":266,"text":184},{"id":194,"depth":266,"text":194},{"id":220,"depth":266,"text":220},"markdown","content:blog:zh:retatrutide-triumph-1-results.md","content","blog\u002Fzh\u002Fretatrutide-triumph-1-results.md","blog\u002Fzh\u002Fretatrutide-triumph-1-results","md"]